Skip to main content
. 2021 Apr 7;21:326. doi: 10.1186/s12879-021-06018-6

Fig. 4.

Fig. 4

Meta-analysis of safety of artemisinin combination therapy administration (PR: DerSimonian-larid random-effects untransformed proportion). Abbreviations: - C.I.: confidence interval, n: events, N: total in the intention-to-treat analysis, CDA: Chlorproguanil-dapsone-artesunate, AL: Artemether–Lumefantrine, DP: dihydroartemisinin-piperaquine, ASAQ: Artesunate–Amodiaquine, PA: pyronaridine-artesunate, ASSMP: Artesunate-Sulphamethoxypyrazine-Pyrimethamine